This report documents that the gastric bypass operation provides long-term control for obesity and diabetes.
Summary Background Data
Obesity and diabetes, both notoriously resistant to medical therapy, continue to be two of our most common and serious diseases.
Methods
Over the last 14 years, 608 morbidly obese patients underwent gastric bypass, an operation that restricts caloric intake by (1) reducing the functional stomach to approximately 30 mL, (2) delaying gastric emptying with a c. 0.8 to 1.0 cm gastric outlet, and (3) excluding foregut with a 40 to 60 cm Roux-en-Y gastrojejunostomy. Even though many of the patients were seriously ill, the operation was performed with a perioperative mortality and complication rate of 1.5% and 8.5%, respectively. Seventeen of the 608 patients (<3%) were lost to follow-up.
Results
Gastric bypass provides durable weight control. Weights fell from a preoperative mean The operation provides long-term control of non-insulin-dependent diabetes mellitus (NIDDM). In those patients with adequate follow-up, 121 of 146 patients (82.9%) with NIDDM and 150 of 152 patients (98.7%) with glucose impairment maintained normal levels of plasma glucose, glycosylated hemoglobin, and insulin. These antidiabetic effects appear to be due primarily to a reduction in caloric intake, suggesting that insulin resistance is a secondary protective effect rather than the initial lesion. In addition to the control of weight and NIDDM, gastric bypass also corrected or alleviated a number of other comorbidities of obesity, including hypertension, sleep apnea, cardiopulmonary failure, arthritis, and infertility.
Of these 608 morbidly obese patients, 165 (27%) had NIDDM, and another 165 (27%) had IGT. Before surgery, 353 (58.1%) ofthe patients had hypertension.
Ofthe initial 608 patients who underwent surgery, 553 of the 574 living patients maintained contact over the 14 years, a follow-up rate of 96.3%. After surgery, 599 (98.5%) survived the perioperative period and 574 (94.4%) are currently alive. Of these, 281 (49%) were examined in the clinic and 272 (47%) were interviewed by phone over the last year. Information was received from the family for 4 (1%) patients, and 17 patients (3%) were lost to follow-up.
Patient Selection
Patients between the ages of 14 and 65 years were accepted for evaluation for bariatric surgery if they had a body mass index (BMI, kg/mi2) of .35 if comorbidities such as diabetes, cardiopulmonary failure, or arthritis existed or .40 if no comorbidities existed. Table 1 shows ideal body weights and BMIs at each height as well as the weights for these heights when BMI values are 24 (considered normal weight by some), 35, and 40. Contraindications to surgery included a history of unresolved alcohol or substance abuse in the previous 5 years, depression, an inability or unwillingness to cooperate in longterm follow-up, a lack of understanding ofthe operation and its consequences, an unrealistic expectation of outcome, and failure to correct the medical conditions to a degree to permit safe surgery. Strong immutable opposition from the family was a relative contraindication.
Preoperative Evaluation and Preparation
The evaluation of these patients as candidates for bariatric surgery was simplified as we gained experience. Even so, we continue to prefer a slow evaluation, that is, over 2 to 3 months, to be certain that the patient and the family are well educated about the operation and its consequences. The first visit is used for the initial evaluation, for the first screening to determine whether the patient is a candidate for bariatric surgery, for the distribution of educational materials, and, if the patient is deemed suitable, for ordering of a psychologic evaluation as well as a chest roentgenogram, upper gastrointestinal series, complete blood count, SMA-17, thyroidstimulating hormone levels, urinalysis, electrocardio- 24  24  23  23  23  23  22  22  22  22  22  22  21  21  21   25  24  24  24  23  23  23  23  22  22  22  22  22  22  22   114   119  122  127  132  135  140   144  149  153  158  162  167  171  177   132  135  140   144  149  153  156  162  167  171  177  181  187  193  197   166  173  178  185  192  197  205  210  217  223  230  236  244  249  258   190  198  203  211  220  225  234  240  248  254  263  270  279  285  295   192  197  205  210  217  223  228  236  244  249  258  264  272  281  287   220  225  234  240  248  254  260  270  279  285  295  301  311  321 It is important to ensure that the intestine is not constricted in its passage through the lesser sac, that the Roux loop is attached to the mesocolon with three sutures to prevent an internal hernia, and that the enteroenterostomy is not bleeding from the internal staple line before applying the TA55. The abdomen is closed with a running double-stranded 0 PDS absorbable suture (Ethicon, Somerville, NJ). The skin is stapled. The operation can usually be performed in 60 to 75 minutes; blood loss rarely exceeds 300 mL. The first 519 gastric partitions were done with a four-row TA90 stapling device. Since then, to avoid further staple line failures, we have either divided the stomach or used the triple superimposed layers of double-row TA90 staples. Except for the different approaches for partition, the operations were identical and can therefore be evaluated as one cohort.
Postoperative Care
The postoperative care of bariatric patients demands close attention. The first 24 hours are particularly critical because ofthe great seriousness ofa leak or intra-abdominal infection in these individuals. If the pulse remains over 120, ifthere is a rise in temperature over 39 C., or if the patient looks ill despite normal vital signs, emergency exploration and additional types of antibiotics may be needed. In such cases, swallow of a small amount of a water-soluble radiopaque agent followed by barium may be helpful to detect an anastomotic leak. (Such tests are not always reliable; we have several patients with leaks who, on the first examination, demonstrated normal passage of barium without extravasation.) Neglect of a perforation or intra-abdominal infection is associated with a high mortality rate. If there is doubt, it is best to proceed with surgery; an unnecessary exploration is a lot safer than a missed perforation.
Patients usually spend the first night on an intermediate unit with nurses who are familiar with bariatric care. Patients are kept on nothing-by-mouth status until they pass flatus, usually on the 3rd day, begun on halfstrength Ensure Plus (30 mL four times daily) with water (30 mL every hour) on the 4th day, and full-strength Ensure Plus with water, in the same doses, on the 5th or 6th day, when they are sent home. After discharge, the patients are maintained on full fluids for 2 weeks and then cautiously progress to a full diet by the end of 6 weeks. Most patients gradually return to their previous diet in terms of variety but with a marked reduction in quantity, because they fill up quickly and because the gastric pouch empties slowly. Most patients cannot tolerate simple carbohydrates, such as candy, because ofthe dumping induced by the gastroenterostomy. Meats may present difficulties: we start slowly with fish, then progress to chicken, and finally, after some months, introduce red meat. By the end of 3 months, most patients eat a limited but well-balanced diet. Considerable counseling may be needed during the initial adjustment to the operation so that the patients understand that the emesis after overeating and the dumping after the ingestion of candy are desirable side effects of the operation and that these symptoms can be avoided by adherence to the dietary limitations.
The most common early complications seen in the clinic are wound abscesses, and these, as might be expected, occur most commonly in the diabetic patients. The wound infections generally present as red bulges that drain spontaneously or that can be drained through a small 1 (1) define the stomach and the alimentary limb, (2) expose the pouch and previous anastomosis, (3) resect the old staple line and the gastroenterostomy, and (4) reanastomose the jejunal limb to the now-divided gastric pouch (Fig. 2) .
RESULTS

Control of Disease
The operation produced significant and durable weight loss. Table 2 demonstrates that the mean preoperative weight of 304.4 lb (range, 198 to 615 lb) drops to 192.2 lb (range, 104 to 466 lb) by the 1st year, a decrease of 112 lb. Usually there is some additional loss by 18 months, followed by a remarkable stability of weight for almost a decade and a half: 205.4 lb (range, 107 to 512 lb) at 5 years, 206.2 lb (range, 130 to 388 lb) at 10 years, and 204.7 lb (range, 158 to 270 lb) at 14 years. Not only has the mean weight ofthese patients at 14 years dropped 100 lb below their operative weights, but also, the maximum weights have diminished even more significantly, from 615 lb to 270 lb. An average maximum weight loss of 70% of excess body weight occurred approximately 2 years after surgery. At the end of 5 years, mean weight loss was 58% of excess body weight; after 10 years, 55%; and after 14 years, 49%. Similarly, the mean BMI levels fell from 49.7 to 31.5, 33.7, 34.7, and 34.9 at 1, 5, 10, and 14 years, respectively. The durability of the weight loss is graphically illustrated in Figure 3 .
Gastric bypass effectively reduced the proportion of body fat. Measurements of body composition with hydrodensitometry (underwater immersion weighing) in 220 randomly selected patients demonstrated that the percentage of fat in females fell from a preoperative mean of 50.92% to 38.46% and in males from 46.70% to 31.93%.
Even more striking is the control of adult-onset diabetes. Before surgery, 165 of 608 patients (27%) had NIDDM and another 165 patients (27%) had IGT, however, a full set of data was not available for 19 ofthe 608 patients for technical reasons. Adequate follow-up data are available on 298 glucose-intolerant patients following surgery, 146 of 165 (88.5%) with NIDDM and 152 of 165 (92.1%) with IGT. Of these 298 patients, 271 (9 1%) have maintained normal values of fasting blood glucose and glycosylated hemoglobin, whereas 27 (9%) continue to be diabetic. Among these 27 diabetic patients, 25 originally presented with NIDDM and 2 with IGT. As of September 12, 1994 , the date of the last annual summary, 121 of 146 patients (82.9%) who presented with NIDDM maintained normal values ofblood glucose and glycosylated hemoglobin.
The 165 patients with IGT were followed until death The normalization of glucose metabolism occurred with surprising speed, even before there was significant weight loss. Figure 4 demonstrates the response in patient 1, whose blood sugar levels were almost uncontrollable, with a fasting blood glucose of 495 mg/dL, despite administration of 90 U of insulin on the day before surgery. By the 6th postoperative day, she no longer required insulin, and by the end of the first month, her fasting blood glucose fell to 155 mg/dL. Within 3 months, her fasting blood glucose and glycosylated hemoglobin levels returned to normal. Figure 5 compares the changes in glucose and insulin levels in three groups: morbidly obese patients with NIDDM, morbidly obese non-NIDDM patients, and lean control subjects. The rapid fall in glucose levels in the patients with NIDDM contrasts sharply with the mild elevation ofboth ofthese indices in the nondiabetic group after surgery, thus fasting alone may not account for the euglycemia in the NIDDM and IGT groups. The differences in insulin levels among the three groups are also shown.
A review of the 27 failed operations in which the patients did not return to euglycemia revealed that 10 of these failures were due to staple line breakdowns, that is, technical failures prevented their correction. When the 17 nonresponders with intact operations, that is, without staple line breakdowns or anastomotic dilatation, were compared with those patients with full control of diabetic indices, the data showed that the patients who failed to revert to full euglycemia were older (48.0 vs. 40.7 years; p < 0.01) and their diabetes was of longer duration (4.6 vs. 1.6 years; p < 0.04) than those with successful control ofglucose and insulin levels.
It is also ofinterest that the gastric bypass can overcorrect the hyperglycemia. We have documented 43 episodes of hypoglycemia in 35 patients, 6 of whom were from the NIDDM cohort, 1 from those with insulin-dependent diabetes mellitus, 8 DAY OUT FROM GASTRIC SURGERY be troublesome, with blood glucose levels as low as 27 mg/dL. We have treated these without therapeutic intervention, urging these patients to carry sugar, and most were self-limited, with corrections occurring usually within 1 year.
Before surgery, 353 of the 608 patients (58.1%) had hypertension. After surgery, this rate has been reduced to 14%. In addition to these improvements, patients almost always demonstrated improvement of cardiopulmonary function, clearance of sleep apnea, cessation of snoring, control of asthma, clearance of peptic reflux, fewer limitations ofphysical activity from arthritis, and restoration of fertility. Mental health evaluations revealed marked overall improvement in mood and mental health indicators during the first 2 years after surgery. These gains, however, eroded by the 3rd year, with a return to their previous mood status, perhaps because some oftheir personal dreams in terms ofmates or socioeconomic success were unrealized.
Complications
Complications diminished with increasing experience and rose with the severity of the comorbidities. For the whole series, including some patients with daunting risks, perioperative mortality was 9 of 608 (1.5%), with 5 dying of sepsis, 3 of pulmonary embolism, and 1 of an unknown cause (perhaps dysrhythmias) shortly after discharge. Perioperative morbidity, that is, during the first 30 days, included the following complications: minor wound infections, 8.7%; wound seromas, 5.8%; severe wound infections, 3.0%; anastomotic stenosis, 3.0%; splenic tears, 2.5%; and subphrenic abscesses, 2.5%. Hospital readmissions were required for 8.2% ofthe patients, and 2.8% of the patients needed reoperations during the early postoperative period. The total mortality over the 14 years was 34 of 608, with 9 perioperative and 25 late deaths. The latter were divided into two groups, 13 from emotionally related causes and 12 due to "more natural" causes. The emotionally related deaths involved three suicides, three cases of cirrhosis due to a return to drinking, one case of bulimia, one case of pernicious anemia due to a refusal to take vitamin B12, one case ofalcoholic hepatitis, and four, perhaps more questionable, cases of auto accidents. (Even though we have begun a regular support group, there have been three such deaths in the 3 years since its commencement.) The other late "natural" deaths included four of cardiac causes, two of cancer, and one each of atherosclerosis, pneumonia, acquired immunodeficiency syndrome, peritonitis, pulmonary embolus, and sepsis from a later operation.
The most frequent late complications were B12 deficiency (40%), anemia (39%), hospital readmission (38. 1%), incisional hernia (23.9%), depression (23.4%), staple line failure (15. 1%), gastritis (13.2%), cholelithiasis (1 1.4%), and bile reflux (8.7%). Dumping syndrome developed in 70.6% of the patients, but although this syndrome is sometimes listed as a complication, it is easily controlled by the avoidance of sweets and is actually a desired side effect.
DISCUSSION
The importance of our findings is not that gastric bypass can control diabetes in the morbidly obese, but that NIDDM, previously considered a progressive and inexorable disease, can be controlled for as long as 14 years.
What is the explanation for this remarkable control? We can immediately rule out several of the traditional approaches used in the treatment of NIDDM: exercise, sulfonylureas, and insulin. None of these play a role in the operative correction of diabetes. Morbidly obese patients do not exercise immediately after surgery, sulfonylureas are never given after the operation, and insulin, even when required initially for the 1st few postoperative days, is rarely needed after the 1st week. The reason for success must be associated with one of the changes induced by surgery:
1. Limitation oftotal caloric intake. 2. Decrease of carbohydrates in the diet (sweets cause dumping). 3. Exclusion of food from the hormonally active antrum, duodenum, and proximaljejunum by the bypass. 4. Delayed transit time from the stomach to the small bowel because ofthe small gastric outlet. 5. Presentation of the midjejunum with undigested food directly from the stomach. There are several observations that offer clues in sorting out the role of each ofthese changes:
1. The correction ofNIDDM occurs within days, long before significant weight loss has occurred and long before there is a significant reduction in the mass of adipocytes. 2. The correction of NIDDM is durable even though most of these patients remain obese. (Although the morbid obesity is almost always "cured," most patients do not return to an ideal body weight, but remain, on the average, 50% above their ideal body weight.) 3. The operation prevents the progression of IGT to NIDDM in 97.8% of the patients and, instead, returns them to euglycemia. 4. The correction of the NIDDM is less likely in paAnn. Surg. -September 1995 tients who are older (48.0 vs. 40.7 years; p < 0.01) and who have had the disease longer (4.6 vs. 1.6 years; p < 0.04), probably due to a lower cell reserve. 5. In the three morbidly obese patients with NIDDM who underwent the vertical banded gastroplasty, an operation that also limits food intake but does not bypass any section of the foregut, the diabetes was also corrected. 6. In a unique patient who had a sham operation, the NIDDM also resolved rapidly when the patient was given the same postoperative diet as the patients who were treated with the gastric bypass. (The patient, a 48-year-old morbidly obese man with NIDDM, was scheduled for a gastric bypass but during surgery was found to have a stomach full of food. We did not, therefore, proceed with the procedure but closed his incision and then requested that he stay on the identical postoperative regimen as if he had undergone the bypass. His levels of blood glucose fell rapidly, similar to the correction seen in the gastric bypass patients, but rose again to preoperative levels as soon as he was unable to maintain the diet, 4 weeks after the procedure.)
Accordingly, based on these observations, it is reasonable to conclude that the gastric bypass controls NIDDM through the reduction of caloric intake. Whether the realignment of intestinal flow with the exclusion ofthe antrum, duodenum, and proximal jejunum as well as the presentation of undigested food to the midjejunum plays an additional role is not known, because we lack a definitive comparison between the effects ofthe gastric bypass and the gastroplasty. The observation by Sugerman's group3 that gut hormone changes are more profound with the bypass than with the vertical banded gastroplasty suggests that such a comparison may demonstrate additional effects ofthe bypass on glucose metabolism.
The relationship between obesity, that is, the increased intake of food, and diabetes and the improvement of diabetes with weight control was noted even in the earliest descriptions of the disease. Most patients older than age 50 with NIDDM are overweight.4 However, dietary control of NIDDM has generally been disappointing. Although diets can improve glucose metabolism in the obese, the improvement usually represents only a partial and usually brief return to euglycemia, even when patients appear to comply. In the study of the effect of diet on diabetes by Doar et al.,5 18 obese patients with newly diagnosed NIDDM were subjected to a rigorous diet that produced a significant weight loss of 5.1 ± 4.0 kg within 2 months. Even so, the average reduction in the fasting plasma glucose was only from approximately 250 to 170 mg/dL, and random blood glucose levels were below 140 mg/dL in only 59% of the group. Although these values reflect improvement, the reversal of NIDDM is not nearly so complete as it is after the gastric bypass.
Our studies of insulin resistance at the cellular level also support the theory that NIDDM is the result of obesity, that is, increased food intake. Because muscle is the site of utilization of approximately 80% of the glucose ingested in a meal, we studied the mechanism(s) causing insulin resistance in rectus abdominis muscle oflean and obese patients undergoing abdominal surgery. Very thin muscle fiber strips were incubated in vitro to make metabolic measurements, including rates of glucose transport, glycogen synthesis, and glycolysis. 6 With this preparation, we demonstrated that insulin stimulation of glucose transport, which is the limiting step in glucose utilization, is depressed in muscle7 of morbidly obese patients with or without diabetes. The degree of insulin resistance is correlated with the degree of obesity up to a body mass index of approximately 30,8 after which there is little further change.
If NIDDM can be controlled so completely by the reduction of caloric intake followed by a rapid decrease in insulin levels and insulin resistance long before there is any significant reduction in the mass of adipose tissue, it is also reasonable to conclude that the lesion of NIDDM must be related to food intake and the signaling mechanisms stimulated by that food. If that hypothesis is true, it follows that the increased insulin resistance ofNIDDM may not be the cause, but rather, an effect of the disease. What are these signaling mechanisms? The gastrointestinal tract, on contact with food and especially with carbohydrates, stimulates insulin secretion through the release of endocrine transmitters, also known as incretins. The incretin effect denotes the phenomenon that glucose elicits a higher f-cell secretory response when administered through the gut as compared with the intravenous route. Increting hormones, then, are endocrine insulinotropic factors released from the gut in response to glucose (or, less strictly, nutrient) ingestion. Two gut peptides have been identified as incretins: glucagon-like peptide-1 (7 to 36) amide (glucagon-like insulinotropic peptide) and glucose-dependent insulinotropic polypeptide (gastric inhibitory peptide).9-12 (None of the other peptides from the gut, that is, cholecystokinin, gastrin, or secretin, are thought to be involved in the regulation of insulin in humans.) There may be other incretins that are unidentified. For further information, refer to Creutzfeldt and Nauck. 12 The errors in signaling probably are not confined to the gut. Further evidence of a broader faulty glucose metabolism signaling system is our finding that decreased Figure 6 , the islets in the morbidly obese patients with NIDDM are initially normal and are able to produce three times as much insulin as those of healthy control subjects before finally failing under the continued stimulation, perhaps due to accumulation of amylin faster than it can be cleared.
The lesion of NIDDM, however, is not based on high food intake alone. Genetics clearly plays an important, but still undefined, role. One third ofour morbidly obese patients have normal glucose metabolism, despite massive obesity. These patients appear to have a different distribution offat as well, with a greater tendency to be pearshaped than apple-shaped, that is, the patients without diabetes have a gynecoid appearance, with the fat distributed to hips and breasts, rather than the android conformation, with a large concentration of abdominal fat. Most of our patients with NIDDM have strong family histories of diabetes.
Differences in the characteristics and genetic expressions of the adipocytes from the NIDDM and non-NIDDM morbidly obese patients are being studied in several centers, including ours. We have conducted studies that revealed differences in the physical, chemical, and biologic properties ofplasma lipoproteins in insulinresistant patients compared with that of insulin-responsive subjects. Plasma low-density lipoprotein (LDL) molecules of insulin-resistant patients tended to be smaller and more dense than LDL of control patients. These changes in the physical properties of LDL could be attributed to changes in the chemical composition of LDL, which included a decrease in the cholesterol ester content and an increase in the protein content of these particles.'9 The changes in the physical and chemical properties ofthe lipoproteins appear to affect the biologic function of LDL, as is evident from our studies. We have shown that cells that depend on exogenous cholesterol for growth and proliferation did not grow as fast when cultured in the presence of LDL of insulin-resistant patients, compared with cells grown in the presence ofLDL Vol. 222 * No. 3 ofcontrol patients. We confirmed these findings with a comparison of the properties of LDL in morbidly obese patients with NIDDM before and after gastric bypass surgery.
Study Limitations
There are several limitations to our study and our hypothesis. First, the claim that NIDDM is controlled by the gastric bypass needs to be supported with evidence that the complications of diabetes are also avoided. We are encouraged by our finding in these patients that LDL reverted to a more normal pattern with respect to physical, chemical, and biologic properties.2' There is also some evidence in patients with NIDDM that the level of glycemic control is a major predictor of the early development of proliferative retinopathy and that hyperinsulinemia is a factor in the progression of coronary artery disease.22 (Whether these conclusions can be extrapolated to patients with NIDDM remain unclear.) Even so, although it is true that none of our 608 patients have suffered renal failure, progressed to blindness, or required an amputation, our group is too small in terms of statistical power for us to claim that the gastric bypass prevents diabetic system failures.
The second limitation is the lack of assays of glucosedependent insulinotropic polypeptide and glucagon-like insulinotropic peptide to support the hypothesis (1) that these incretin levels are high in the morbidly obese, (2) that high incretin levels can cause exhaustion of the islets, and (3) that these levels fall after bariatric procedures. We have recently sent specimens, drawn from NIDDM subjects before and after bariatric surgery, for analysis to such as the gastroplasties, produce similar levels of control remains to be determined. Why the operation controls diabetes so well is not clear, but the major reason appears to be the reduction of caloric intake. There is some evidence that changes in the incretin stimulation of the islets by the gut may also play a role.
These studies provide new insights and opportunities to understand NIDDM and predict, with control of obesity, that this devastating disease may be curable.
Discussion
DR. LLOYD D. MACLEAN (Montreal, Quebec): I agree that surgery for obesity is gaining acceptance within the medical profession. This is in no small measure, I think, due to the efforts of Dr. Pories and his colleagues. It is also due to the willingness of the American Surgical Association to hear of the interests of its members, no matter how controversial. The first paper on this was given by Arnold Kremen in 1954. Some of you will remember that.
Dr. Pories has reported a large series with impressive results, and an even more remarkable follow-up, which he did not emphasize during his presentation.
We perform a similar operation with a small pouch, 10 to 15 mL. It is isolated from the rest of the stomach and the fundic side is inverted so there can be no mucosa-to-mucosa approximation. The operation is not dependent on staples. It is placed in the dependent position along the lesser curve ofthe stomach so there is no enlargement of the pouch over time. In contrast to Dr. Pories, we have made the anastomosis initially with a running nonabsorbable Prolene suture (Ethicon, Somerville, NJ). But when we rescoped those people 1 or 2 years later, we invariably found the Prolene in the lumen. The anastomosis was the size of the jejunum and not confined by the running suture.
We have gone on to perform this operation without any attempt at narrowing the anastomosis using an absorbable suture. On 160 patients who have been followed between 3 and 7 years, 95% have a satisfactory result; that is, they are within 50% of ideal weight.
This only held for morbid obesity, that is, a body mass index between 40 and 50 and when a primary operation was performed. If it was a redo or revision operation, or if the patient was super obese with a body mass index over 50, our results were only 63% satisfactory. I wonder if Dr. Pories could comment on that.
Ann. Surg. * September 1995 I have four very briefquestions. How many ofyour patients do return to within 50% ofideal? You give your results as means with a wide variation around the mean; it is a little difficult to tell how many patients got a satisfactory result.
You have made a very good point that visceral obesity is associated with insulin resistance, hyperinsulinemia, and impaired glucose intolerance. In addition, I think you have data that are not in the paper on the dyslipedemic state, which is the strongest, after smoking, predisposing factor for coronary artery disease. I would be very interested in the incidence of coronary artery disease in your 600 patients. Is this less than might be expected in this group? Do they have to lose more weight than you have found so effective in the treatment oftype 2 diabetes? There is a genetic predisposition to severe obesity and its distribution. I wonder, does a strong family history influence the likelihood ofa successful result?
Finally, fewer super obese patients in our experience return to normal. I wonder if this has been your experience? And I wonder why that is? Do they eat more despite the operation than morbidly obese people?
The suggestion has been made by the recent cloning of an obesity gene that the product of that is a satiety substance released from fat cells throughout the body. This works in an exceedingly efficient manner for most of us, who gain approximately 10 kg over 20 years ofadulthood, which is equivalent to about one too many carrot sticks a day.
I suspect this is a central defect in these people and they could have all the satiety hormone floating around that they would need, but it will not help and you will still have to operate on those people. In the accompanying editorial, there is no mention ofgastric surgery for obesity, but the possibility ofbrain surgery is raised (Bennett W. Beyond overeating. N Engl J Med 1995: 332:673-674).
The 14-year follow-up of gastric bypass patients from the Greenville, North Carolina group under the leadership of Dr. Pories emphasizes the dramatic long-term success this operation can provide. In addition to diabetes, it effectively reverses in most patients hypertension, sleep apnea, obesity hyperventilation, pseudo-tumor cerebri, venous stasis ulcers, gastroesophageal reflux, etc.
There are several other published studies, including our own, documenting the long-term efficacy of gastric bypass for this "intractable" problem.
In a previous study of glucose tolerance tests before and 1 year after vertical-banded gastroplasty or gastric bypass in severely obese patients who did not require medication for diabetes, we noted that the gastric bypass was associated with the loss of 65% of excess weight, and vertical-banded gastroplasty,
